ACTRN12616000002482
Completed
Phase 1
A Phase 1 Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Chronic rhinosinusitis
- Sponsor
- The Queen Elizabeth Hospital
- Enrollment
- 9
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Participants must have had at least two of the following symptoms of chronic rhinosinusitis (nasal discharge, postnasal drip, nasal obstruction, facial pain and pressure or lack of sense of smell) that has been previously persistent for greater than 3 months.
- •2\.Participants must have had at least one operation for their chronic rhinosinusitis but should be at least 6 weeks post\- operative.
- •3\.Participants must have a positive sinonasal swab that indicates infection of S. aureus in the sinuses that is sensitive to AB\-SA01 within 14 days of enrolment.
- •4\.Participants must show evidence of chronic sinusitis by direct endoscopic examination.
- •5\.Participants must have the ability to administer nasal lavage twice daily for the duration of the treatment period.
- •6\.Participants must have impaired quality of life as measured by RSDI.
- •7\.Participants must be male or female aged between 18 and 70 years.
- •8\.Participants must be able to give written informed consent.
- •9\.Participants must have the ability and willingness to attend several visits to the study centre.
- •10\.Participants must have the willingness and ability to comply with the requirements of the protocol as determined by the Investigator.
Exclusion Criteria
- •1\.1\.Participants with a diagnosis of cystic fibrosis or ciliary dyskinesia.
- •2\.Female participants who are pregnant or breastfeeding.
- •3\.Participants who are immunocompromised.
- •4\.Participants who are actively taking oral steroids or antibiotics.
- •5\.Participants who have used antibiotics within 1 month prior to screening.
- •6\.Participants who have been on active trial therapy within one month of screening.
- •7\.Participants who have a positive sinonasal swab that indicates presence of P. aeruginosa in the sinuses.
- •8\.Any clinically significant laboratory abnormality.
- •9\.Participants who are unlikely to comply with the study protocol or, in the opinion of the investigator, would not be a suitable candidate for participation in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Trail with Corneal ImplantHealth Condition 1: H171- Central corneal opacityHealth Condition 2: null- Corneal Edema with No Visual PotentialCTRI/2019/07/020024Eye Yon Medical Ltd
Recruiting
Not Applicable
Continuous mONitoring of recovery iN acutE isChaemic sTroke (CONNECT) - Phase 1ACTRN12622001485729The George Institute50
Active, not recruiting
Not Applicable
Study to see the Safety and Effectiveness of a custom made Porcine lens named as XeniaTM after implanting in patients having Keratoconus meaning Thin and Irregular corneaCTRI/2021/04/033197Mr Steffen Gebauer5
Not yet recruiting
Not Applicable
A study to evaluate the safety of immune cell therapy in early transplant period of hematopoietic stem cell transplant recipientsKCT0004024The Catholic University of Korea, Seoul St. Mary's Hospital32
Active, not recruiting
Phase 2
Investigator-initiated phase II trial to evaluate the efficacy and safety of Acotiamide in patients with esophagogastric junction outflow obstructioJPRN-jRCT2071210072Ihara Eikichi42